{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:47:39Z","timestamp":1792079259645,"version":"4.4.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,9,22]],"date-time":"2013-09-22T00:00:00Z","timestamp":1379808000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Apoptosis"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1007\/s10495-013-0906-7","type":"journal-article","created":{"date-parts":[[2013,9,21]],"date-time":"2013-09-21T14:26:09Z","timestamp":1379773569000},"page":"191-200","source":"Crossref","is-referenced-by-count":20,"title":["Valproic acid enhances fludarabine-induced apoptosis mediated by ROS and involving decreased AKT and ATM activation in B-cell-lymphoid neoplastic cells"],"prefix":"10.1007","volume":"19","author":[{"given":"Ju-Yoon","family":"Yoon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganchimeg","family":"Ishdorj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bonnie A.","family":"Graham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James B.","family":"Johnston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Spencer B.","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,9,22]]},"reference":[{"issue":"12","key":"906_CR1","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1517\/14656566.7.12.1641","volume":"7","author":"T Elter","year":"2006","unstructured":"Elter T, Hallek M, Engert A (2006) Fludarabine in chronic lymphocytic leukaemia. Expert Opin Pharmacother 7(12):1641\u20131651. doi: 10.1517\/14656566.7.12.1641","journal-title":"Expert Opin Pharmacother"},{"issue":"9747","key":"906_CR2","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","volume":"376","author":"M Hallek","year":"2010","unstructured":"Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, Hensel M, Hopfinger G, Hess G, von Gr\u00fcnhagen U, Bergmann M, Catalano J, Zinzani PL, Caligaris-Cappio F, Seymour JF, Berrebi A, J\u00e4ger U, Cazin B, Trneny M, Westermann A, Wendtner CM, Eichhorst BF, Staib P, B\u00fchler A, Winkler D, Zenz T, B\u00f6ttcher S, Ritgen M, Mendila M, Kneba M, D\u00f6hner H, Stilgenbauer S (2010) Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet 376(9747):1164\u20131174","journal-title":"Lancet"},{"issue":"8","key":"906_CR3","doi-asserted-by":"crossref","first-page":"507","DOI":"10.3816\/CLM.2007.n.034","volume":"7","author":"R Mihelic","year":"2007","unstructured":"Mihelic R, Kaufman J, Lonial S, Flowers C (2007) Maintenance therapy in lymphoma. Clin lymphoma Myeloma 7(8):507\u2013513","journal-title":"Clin lymphoma Myeloma"},{"issue":"11","key":"906_CR4","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.2165\/00003495-200767110-00008","volume":"67","author":"VR Anderson","year":"2007","unstructured":"Anderson VR, Perry CM (2007) Fludarabine: a review of its use in non-Hodgkin\u2019s lymphoma. Drugs 67(11):1633\u20131655","journal-title":"Drugs"},{"issue":"1","key":"906_CR5","doi-asserted-by":"crossref","first-page":"35","DOI":"10.4149\/neo_2011_01_35","volume":"58","author":"K Elknerova","year":"2011","unstructured":"Elknerova K, Myslivcova D, Lacinova Z, Marinov I, Uherkova L, Stockbauer P (2011) Epigenetic modulation of gene expression of human leukemia cell lines: induction of cell death and senescence. Neoplasma 58(1):35\u201344","journal-title":"Neoplasma"},{"issue":"3","key":"906_CR6","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1182\/blood-2004-05-1693","volume":"105","author":"JC Byrd","year":"2005","unstructured":"Byrd JC, Marcucci G, Parthun MR, Xiao JJ, Klisovic RB, Moran M, Lin TS, Liu S, Sklenar AR, Davis ME, Lucas DM, Fischer B, Shank R, Tejaswi SL, Binkley P, Wright J, Chan KK, Grever MR (2005) A phase 1 and pharmacodynamic study of depsipeptide (FK228) in chronic lymphocytic leukemia and acute myeloid leukemia. Blood 105(3):959\u2013967. doi: 10.1182\/blood-2004-05-1693","journal-title":"Blood"},{"issue":"4","key":"906_CR7","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1111\/j.1365-2141.2009.07881.x","volume":"147","author":"KA Blum","year":"2009","unstructured":"Blum KA, Advani A, Fernandez L, Van Der Jagt R, Brandwein J, Kambhampati S, Kassis J, Davis M, Bonfils C, Dubay M, Dumouchel J, Drouin M, Lucas DM, Martell RE, Byrd JC (2009) Phase II study of the histone deacetylase inhibitor MGCD0103 in patients with previously treated chronic lymphocytic leukaemia. Br J Haematol 147(4):507\u2013514. doi: 10.1111\/j.1365-2141.2009.07881.x","journal-title":"Br J Haematol"},{"issue":"24","key":"906_CR8","doi-asserted-by":"crossref","first-page":"6969","DOI":"10.1093\/emboj\/20.24.6969","volume":"20","author":"M Gottlicher","year":"2001","unstructured":"Gottlicher M, Minucci S, Zhu P, Kramer OH, Schimpf A, Giavara S, Sleeman JP, Lo Coco F, Nervi C, Pelicci PG, Heinzel T (2001) Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 20(24):6969\u20136978","journal-title":"EMBO J"},{"issue":"3","key":"906_CR9","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1158\/0008-5472.CAN-03-0799","volume":"64","author":"N Gurvich","year":"2004","unstructured":"Gurvich N, Tsygankova OM, Meinkoth JL, Klein PS (2004) Histone deacetylase is a target of valproic acid-mediated cellular differentiation. Cancer Res 64(3):1079\u20131086. doi: 10.1158\/0008-5472.can-03-0799","journal-title":"Cancer Res"},{"issue":"3","key":"906_CR10","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nbt.1759","volume":"29","author":"M Bantscheff","year":"2011","unstructured":"Bantscheff M, Hopf C, Savitski MM, Dittmann A, Grandi P, Michon A-M, Schlegl J, Abraham Y, Becher I, Bergamini G, Boesche M, Delling M, Dumpelfeld B, Eberhard D, Huthmacher C, Mathieson T, Poeckel D, Reader V, Strunk K, Sweetman G, Kruse U, Neubauer G, Ramsden NG, Drewes G (2011) Chemoproteomics profiling of HDAC inhibitors reveals selective targeting of HDAC complexes. Nat Biotech 29(3):255\u2013265","journal-title":"Nat Biotech"},{"issue":"1","key":"906_CR11","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1365-2141.2008.07426.x","volume":"144","author":"AB Bouzar","year":"2009","unstructured":"Bouzar AB, Boxus M, Defoiche J, Berchem G, Macallan D, Pettengell R, Willis F, Burny A, Lagneaux L, Bron D, Chatelain B, Chatelain C, Willems L (2009) Valproate synergizes with purine nucleoside analogues to induce apoptosis of B-chronic lymphocytic leukaemia cells. Br J Haematol 144(1):41\u201352. doi: 10.1111\/j.1365-2141.2008.07426.x","journal-title":"Br J Haematol"},{"issue":"10","key":"906_CR12","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1016\/j.exphem.2007.06.014","volume":"35","author":"L Lagneaux","year":"2007","unstructured":"Lagneaux L, Gillet N, Stamatopoulos B, Delforge A, Dejeneffe M, Massy M, Meuleman N, Kentos A, Martiat P, Willems L, Bron D (2007) Valproic acid induces apoptosis in chronic lymphocytic leukemia cells through activation of the death receptor pathway and potentiates TRAIL response. Exp Hematol 35(10):1527\u20131537. doi: 10.1016\/j.exphem.2007.06.014","journal-title":"Exp Hematol"},{"issue":"12","key":"906_CR13","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1038\/leu.2009.176","volume":"23","author":"B Stamatopoulos","year":"2009","unstructured":"Stamatopoulos B, Meuleman N, De Bruyn C, Mineur P, Martiat P, Bron D, Lagneaux L (2009) Antileukemic activity of valproic acid in chronic lymphocytic leukemia B cells defined by microarray analysis. Leukemia 23(12):2281\u20132289","journal-title":"Leukemia"},{"issue":"1\u20132","key":"906_CR14","doi-asserted-by":"crossref","first-page":"20","DOI":"10.2119\/2007-00084.Bokelmann","volume":"14","author":"I Bokelmann","year":"2008","unstructured":"Bokelmann I, Mahlknecht U (2008) Valproic acid sensitizes chronic lymphocytic leukemia cells to apoptosis and restores the balance between pro- and antiapoptotic proteins. Mol Med 14(1\u20132):20\u201327. doi: 10.2119\/2007-00084.Bokelmann","journal-title":"Mol Med"},{"issue":"51","key":"906_CR15","doi-asserted-by":"crossref","first-page":"8356","DOI":"10.1038\/sj.onc.1207004","volume":"22","author":"JB Johnston","year":"2003","unstructured":"Johnston JB, Kabore AF, Strutinsky J, Hu X, Paul JT, Kropp DM, Kuschak B, Begleiter A, Gibson SB (2003) Role of the TRAIL\/\/APO2-L death receptors in chlorambucil- and fludarabine-induced apoptosis in chronic lymphocytic leukemia. Oncogene 22(51):8356\u20138369","journal-title":"Oncogene"},{"issue":"3","key":"906_CR16","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1038\/nprot.2006.238","volume":"1","author":"C Riccardi","year":"2006","unstructured":"Riccardi C, Nicoletti I (2006) Analysis of apoptosis by propidium iodide staining and flow cytometry. Nat Protocols 1(3):1458\u20131461","journal-title":"Nat Protocols"},{"key":"906_CR17","doi-asserted-by":"crossref","unstructured":"Yoon JY, Szwajcer D, Ishdorj G, Benjaminson P, Kumar R, Johnston J, Xaio W, Gibson SB (2013) Synergistic apoptotic response between valproic acid and fludarabine in chronic lymphocytic leukemia (CLL) cells involves the lysosomal protease cathepsin B. Blood Cancer J (Accepted)","DOI":"10.1038\/bcj.2013.50"},{"issue":"2","key":"906_CR18","doi-asserted-by":"crossref","first-page":"147","DOI":"10.2174\/1568009043481551","volume":"4","author":"AF Kabore","year":"2004","unstructured":"Kabore AF, Johnston JB, Gibson SB (2004) Changes in the apoptotic and survival signaling in cancer cells and their potential therapeutic implications. Curr Cancer Drug Targets 4(2):147\u2013163","journal-title":"Curr Cancer Drug Targets"},{"issue":"1","key":"906_CR19","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1080\/10428190701713655","volume":"49","author":"ES Henson","year":"2008","unstructured":"Henson ES, Johnston JB, Gibson SB (2008) The role of TRAIL death receptors in the treatment of hematological malignancies. Leuk Lymphoma 49(1):27\u201335","journal-title":"Leuk Lymphoma"},{"issue":"13","key":"906_CR20","doi-asserted-by":"crossref","first-page":"6785","DOI":"10.1158\/0008-5472.CAN-05-4563","volume":"66","author":"S Inoue","year":"2006","unstructured":"Inoue S, Mai A, Dyer MJS, Cohen GM (2006) Inhibition of histone deacetylase class I but not class II is critical for the sensitization of leukemic cells to tumor necrosis factor\u2013related apoptosis-inducing ligand\u2013induced apoptosis. Cancer Res 66(13):6785\u20136792. doi: 10.1158\/0008-5472.can-05-4563","journal-title":"Cancer Res"},{"issue":"S2","key":"906_CR21","doi-asserted-by":"crossref","first-page":"S193","DOI":"10.1038\/sj.cdd.4401535","volume":"11","author":"S Inoue","year":"2004","unstructured":"Inoue S, MacFarlane M, Harper N, Wheat LMC, Dyer MJS, Cohen GM (2004) Histone deacetylase inhibitors potentiate TNF-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in lymphoid malignancies. Cell Death Differ 11(S2):S193\u2013S206","journal-title":"Cell Death Differ"},{"issue":"46","key":"906_CR22","doi-asserted-by":"crossref","first-page":"38879","DOI":"10.1074\/jbc.M505733200","volume":"280","author":"C-S Chen","year":"2005","unstructured":"Chen C-S, Weng S-C, Tseng P-H, Lin H-P, Chen C-S (2005) Histone acetylation-independent effect of histone deacetylase inhibitors on akt through the reshuffling of protein phosphatase 1 complexes. J Biol Chem 280(46):38879\u201338887. doi: 10.1074\/jbc.M505733200","journal-title":"J Biol Chem"},{"issue":"14","key":"906_CR23","doi-asserted-by":"crossref","first-page":"2926","DOI":"10.1182\/blood-2009-05-220889","volume":"114","author":"M Gupta","year":"2009","unstructured":"Gupta M, Ansell SM, Novak AJ, Kumar S, Kaufmann SH, Witzig TE (2009) Inhibition of histone deacetylase overcomes rapamycin-mediated resistance in diffuse large B-cell lymphoma by inhibiting Akt signaling through mTORC2. Blood 114(14):2926\u20132935. doi: 10.1182\/blood-2009-05-220889","journal-title":"Blood"},{"issue":"18","key":"906_CR24","doi-asserted-by":"crossref","first-page":"18851","DOI":"10.1074\/jbc.M312795200","volume":"279","author":"DC Lagace","year":"2004","unstructured":"Lagace DC, Nachtigal MW (2004) Inhibition of histone deacetylase activity by valproic acid blocks adipogenesis. J Biol Chem 279(18):18851\u201318860. doi: 10.1074\/jbc.M312795200","journal-title":"J Biol Chem"},{"key":"906_CR25","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.4049\/jimmunol.164.4.2200","volume":"164","author":"RR Furman","year":"2000","unstructured":"Furman RR, Asgary Z, Mascarenhas JO, Liou HC, Schattner EJ (2000) Modulation of NF-kappa B activity and apoptosis in chronic lymphocytic leukemia B cells. J Immunol 164:2200\u20132206","journal-title":"J Immunol"},{"issue":"10","key":"906_CR26","doi-asserted-by":"crossref","first-page":"3354","DOI":"10.1158\/1078-0432.CCR-08-2365","volume":"15","author":"S Bhalla","year":"2009","unstructured":"Bhalla S, Balasubramanian S, David K, Sirisawad M, Buggy J, Mauro L, Prachand S, Miller R, Gordon LI, Evens AM (2009) PCI-24781 induces caspase and reactive oxygen species\u2013dependent apoptosis through NF-\u03baB mechanisms and is synergistic with bortezomib in lymphoma cells. Clin Cancer Res 15(10):3354\u20133365. doi: 10.1158\/1078-0432.ccr-08-2365","journal-title":"Clin Cancer Res"},{"issue":"13","key":"906_CR27","doi-asserted-by":"crossref","first-page":"5429","DOI":"10.1128\/MCB.25.13.5429-5444.2005","volume":"25","author":"Y Dai","year":"2005","unstructured":"Dai Y, Rahmani M, Dent P, Grant S (2005) Blockade of histone deacetylase inhibitor-induced RelA\/p65 acetylation and NF-\u03baB activation potentiates apoptosis in leukemia cells through a process mediated by oxidative damage, XIAP downregulation, and c-Jun N-terminal kinase 1 Activation. Mol Cell Biol 25(13):5429\u20135444. doi: 10.1128\/mcb.25.13.5429-5444.2005","journal-title":"Mol Cell Biol"},{"issue":"5","key":"906_CR28","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1038\/sj.leu.2404167","volume":"20","author":"R Horie","year":"2006","unstructured":"Horie R, Watanabe M, Okamura T, Taira M, Shoda M, Motoji T, Utsunomiya A, Watanabe T, Higashihara M, Umezawa K (2006) DHMEQ, a new NF-[kappa]B inhibitor, induces apoptosis and enhances fludarabine effects on chronic lymphocytic leukemia cells. Leukemia 20(5):800\u2013806","journal-title":"Leukemia"},{"issue":"2","key":"906_CR29","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.molcel.2010.09.019","volume":"40","author":"A Ciccia","year":"2010","unstructured":"Ciccia A, Elledge SJ (2010) The DNA damage response: making it safe to play with knives. Mol Cell 40(2):179\u2013204. doi: 10.1016\/j.molcel.2010.09.019","journal-title":"Mol Cell"},{"issue":"2","key":"906_CR30","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/bdrb.20236","volume":"89","author":"K Sha","year":"2010","unstructured":"Sha K, Winn LM (2010) Characterization of valproic acid-initiated homologous recombination. Birth Defects Res B 89(2):124\u2013132. doi: 10.1002\/bdrb.20236","journal-title":"Birth Defects Res B"},{"issue":"4","key":"906_CR31","doi-asserted-by":"crossref","first-page":"468","DOI":"10.4161\/cc.7.4.5405","volume":"7","author":"KN Harikrishnan","year":"2008","unstructured":"Harikrishnan KN, Karagiannis TC, Chow MZ, El-Osta A (2008) Effect of valproic acid on radiation-induced DNA damage in euchromatic and heterochromatic compartments. Cell Cycle 7(4):468\u2013476","journal-title":"Cell Cycle"},{"issue":"24","key":"906_CR32","doi-asserted-by":"crossref","first-page":"9152","DOI":"10.1158\/0008-5472.CAN-04-2727","volume":"64","author":"I Hickson","year":"2004","unstructured":"Hickson I, Zhao Y, Richardson CJ, Green SJ, Martin NMB, Orr AI, Reaper PM, Jackson SP, Curtin NJ, Smith GCM (2004) Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Res 64(24):9152\u20139159. doi: 10.1158\/0008-5472.can-04-2727","journal-title":"Cancer Res"},{"issue":"3","key":"906_CR33","doi-asserted-by":"crossref","first-page":"234","DOI":"10.2174\/1568009611313030002","volume":"13","author":"M Cheung","year":"2013","unstructured":"Cheung M, Testa JR (2013) Diverse mechanisms of AKT pathway activation in human malignancy. Curr Cancer Drug Targets 13(3):234\u2013244","journal-title":"Curr Cancer Drug Targets"},{"issue":"1","key":"906_CR34","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1476-4598-5-71","volume":"5","author":"J Chen","year":"2006","unstructured":"Chen J, Ghazawi F, Bakkar W, Li Q (2006) Valproic acid and butyrate induce apoptosis in human cancer cells through inhibition of gene expression of Akt\/protein kinase B. Mol Cancer 5(1):71","journal-title":"Mol Cancer"},{"issue":"8","key":"906_CR35","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1002\/ijc.24158","volume":"124","author":"L Mologni","year":"2009","unstructured":"Mologni L, Cleris L, Magistroni V, Piazza R, Boschelli F, Formelli F, Gambacorti-Passerini C (2009) Valproic acid enhances bosutinib cytotoxicity in colon cancer cells. Int J Cancer 124(8):1990\u20131996. doi: 10.1002\/ijc.24158","journal-title":"Int J Cancer"},{"issue":"7","key":"906_CR36","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1016\/S0028-3908(02)00215-0","volume":"43","author":"P Sarno De","year":"2002","unstructured":"De Sarno P, Li X, Jope RS (2002) Regulation of Akt and glycogen synthase kinase-3\u03b2 phosphorylation by sodium valproate and lithium. Neuropharmacology 43(7):1158\u20131164. doi: 10.1016\/s0028-3908(02)00215-0","journal-title":"Neuropharmacology"},{"issue":"6","key":"906_CR37","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1182\/blood-2012-02-362624","volume":"120","author":"JA Woyach","year":"2012","unstructured":"Woyach JA, Johnson AJ, Byrd JC (2012) The B-cell receptor signaling pathway as a therapeutic target in CLL. Blood 120(6):1175\u20131184. doi: 10.1182\/blood-2012-02-362624","journal-title":"Blood"},{"issue":"1","key":"906_CR38","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1182\/blood.V90.1.270","volume":"90","author":"H Iwasaki","year":"1997","unstructured":"Iwasaki H, Huang P, Keating MJ, Plunkett W (1997) Differential incorporation of ara-C, gemcitabine, and fludarabine into replicating and repairing DNA in proliferating human leukemia cells. Blood 90(1):270\u2013278","journal-title":"Blood"},{"issue":"6","key":"906_CR39","first-page":"2260","volume":"42","author":"EL White","year":"1982","unstructured":"White EL, Shaddix SC, Brockman RW, Bennett LL (1982) Comparison of the actions of 9-\u03b2-d-arabinofuranosyl-2-fluoroadenine and 9-\u03b2-d-arabinofuranosyladenine on target enzymes from mouse tumor cells. Cancer Res 42(6):2260\u20132264","journal-title":"Cancer Res"},{"issue":"5","key":"906_CR40","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1182\/blood-2003-09-3236","volume":"104","author":"A Rosenwald","year":"2004","unstructured":"Rosenwald A, Chuang EY, Davis RE, Wiestner A, Alizadeh AA, Arthur DC, Mitchell JB, Marti GE, Fowler DH, Wilson WH, Staudt LM (2004) Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response. Blood 104(5):1428\u20131434. doi: 10.1182\/blood-2003-09-3236","journal-title":"Blood"},{"issue":"22","key":"906_CR41","doi-asserted-by":"crossref","first-page":"4578","DOI":"10.1182\/blood-2010-01-265769","volume":"116","author":"VJ Weston","year":"2010","unstructured":"Weston VJ, Oldreive CE, Skowronska A, Oscier DG, Pratt G, Dyer MJS, Smith G, Powell JE, Rudzki Z, Kearns P, Moss PAH, Taylor AMR, Stankovic T (2010) The PARP inhibitor olaparib induces significant killing of ATM-deficient lymphoid tumor cells in vitro and in vivo. Blood 116(22):4578\u20134587. doi: 10.1182\/blood-2010-01-265769","journal-title":"Blood"},{"issue":"2","key":"906_CR42","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1080\/10428190802688517","volume":"50","author":"B Eichhorst","year":"2009","unstructured":"Eichhorst B, Goede V, Hallek M (2009) Treatment of elderly patients with chronic lymphocytic leukemia. Leuk Lymphoma 50(2):171\u2013178. doi: 10.1080\/10428190802688517","journal-title":"Leuk Lymphoma"}],"container-title":["Apoptosis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10495-013-0906-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10495-013-0906-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10495-013-0906-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T01:24:10Z","timestamp":1715995450000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10495-013-0906-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,22]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["906"],"URL":"https:\/\/doi.org\/10.1007\/s10495-013-0906-7","relation":{},"ISSN":["1360-8185","1573-675X"],"issn-type":[{"value":"1360-8185","type":"print"},{"value":"1573-675X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9,22]]}}}